Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dolman

Showing results (131-140 of 165) with videos related to

Pageof 17
Sort By:
The Journal of Rheumatology|January 17, 2018
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic ArthritisFaekah Gohar, Janneke Anink, Halima Moncrieffe, et al.
Cancer Research Communications|July 10, 2025
Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision TherapyNadine Azzam, Jamie I Fletcher, Nicole Melong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Molecular Cancer Therapeutics|April 14, 2021
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsLindy Vernooij, Laurel T Bate-Eya, Lindy K Alles, et al.
Journal of Medicinal Chemistry|November 18, 2025
Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in NeuroblastomaSimon Krols, Muhammad Rishfi, Fien Martens, et al.
Frontiers in Oncology|October 14, 2022
Chromosome 11q loss and <i>MYCN</i> amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaKaylee M Keller, Thomas F Eleveld, Linda Schild, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2021
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignanciesKaylee M Keller, Sonja Krausert, Apurva Gopisetty, et al.
Translational Oncology|March 5, 2021
High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemiaPriscilla Wander, Susan T C J M Arentsen-Peters, Sandra S Pinhanҫos, et al.
Journal of Personalized Medicine|September 28, 2021
Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer ImmunotherapiesWaleed M Kholosy, Marc Derieppe, Femke van den Ham, et al.
Frontiers in Oncology|March 10, 2023
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastomaThomas F Eleveld, Lindy Vernooij, Linda Schild, et al.
Pageof 17

Showing results (131-140 of 165) with videos related to

Sort By:
Pageof 17
The Journal of Rheumatology|January 17, 2018
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic ArthritisFaekah Gohar, Janneke Anink, Halima Moncrieffe, et al.
Cancer Research Communications|July 10, 2025
Modeling High-Risk Pediatric Cancers in Zebrafish to Inform Precision TherapyNadine Azzam, Jamie I Fletcher, Nicole Melong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2015
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaM Emmy M Dolman, Evon Poon, Marli E Ebus, et al.
Molecular Cancer Therapeutics|April 14, 2021
High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsLindy Vernooij, Laurel T Bate-Eya, Lindy K Alles, et al.
Journal of Medicinal Chemistry|November 18, 2025
Second-Generation AURKA-Targeting PROTACs: Structural Optimization toward in Vivo Degradation in NeuroblastomaSimon Krols, Muhammad Rishfi, Fien Martens, et al.
Frontiers in Oncology|October 14, 2022
Chromosome 11q loss and <i>MYCN</i> amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastomaKaylee M Keller, Thomas F Eleveld, Linda Schild, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2021
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignanciesKaylee M Keller, Sonja Krausert, Apurva Gopisetty, et al.
Translational Oncology|March 5, 2021
High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemiaPriscilla Wander, Susan T C J M Arentsen-Peters, Sandra S Pinhanҫos, et al.
Journal of Personalized Medicine|September 28, 2021
Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer ImmunotherapiesWaleed M Kholosy, Marc Derieppe, Femke van den Ham, et al.
Frontiers in Oncology|March 10, 2023
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastomaThomas F Eleveld, Lindy Vernooij, Linda Schild, et al.
Pageof 17